BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27802450)

  • 1. Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer.
    Thurtle D; Hsu RC; Chetan M; Lophatananon A; Hubbard R; Gnanapragasam VJ; Barrett T
    Br J Cancer; 2016 Nov; 115(11):1285-1288. PubMed ID: 27802450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
    Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
    Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
    KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
    BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.
    Kam J; Yuminaga Y; Krelle M; Gavin D; Koschel S; Aluwihare K; Sutherland T; Skinner S; Brennan J; Wong LM; Louie-Johnsun M
    BJU Int; 2019 Aug; 124(2):297-301. PubMed ID: 30714285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do patients who undergo multiparametric MRI for prostate cancer benefit from additional staging imaging? Results from a statewide collaborative.
    Eyrich NW; Tosoian JJ; Drobish J; Montie JE; Qi J; Kim T; Noyes SL; Moriarity AK; Lane BR;
    Urol Oncol; 2020 Jul; 38(7):636.e13-636.e19. PubMed ID: 32067844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
    Pasoglou V; Larbi A; Collette L; Annet L; Jamar F; Machiels JP; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
    Prostate; 2014 May; 74(5):469-77. PubMed ID: 24375774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stratification of the aggressiveness of prostate cancer using pre-biopsy multiparametric MRI (mpMRI).
    Dwivedi DK; Kumar R; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
    NMR Biomed; 2016 Mar; 29(3):232-8. PubMed ID: 26730884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?
    Holtz JN; Silverman RK; Tay KJ; Browning JT; Huang J; Polascik TJ; Gupta RT
    Abdom Radiol (NY); 2018 Mar; 43(3):702-712. PubMed ID: 28721479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    Johnson DC; Raman SS; Mirak SA; Kwan L; Bajgiran AM; Hsu W; Maehara CK; Ahuja P; Faiena I; Pooli A; Salmasi A; Sisk A; Felker ER; Lu DSK; Reiter RE
    Eur Urol; 2019 May; 75(5):712-720. PubMed ID: 30509763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study.
    Thomsen FB; Westerberg M; Garmo H; Robinson D; Holmberg L; Ulmert HD; Stattin P
    PLoS One; 2020; 15(1):e0228447. PubMed ID: 31995611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance.
    Mamawala MK; Meyer AR; Landis PK; Macura KJ; Epstein JI; Partin AW; Carter BH; Gorin MA
    BJU Int; 2020 Jun; 125(6):861-866. PubMed ID: 32039537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric magnetic resonance imaging for the assessment of extracapsular invasion and other staging parameters in patients with prostate cancer candidates for radical prostatectomy.
    Lista F; Gimbernat H; Cáceres F; Rodríguez-Barbero JM; Castillo E; Angulo JC
    Actas Urol Esp; 2014 Jun; 38(5):290-7. PubMed ID: 24387827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
    Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
    Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience.
    Panje C; Panje T; Putora PM; Kim SK; Haile S; Aebersold DM; Plasswilm L
    Radiat Oncol; 2015 Feb; 10():47. PubMed ID: 25880635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.